Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Long-Term Debt of $0.00 for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $314.87M | +3.8% |
| 2023 | $303.23M | +30.9% |
| 2022 | $231.62M | +70.2% |
| 2021 | $136.08M | +13.7% |
| 2020 | $119.73M | — |
| 2019 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $194.37M | -38.2% | -19.9% |
| June 30, 2025 | $242.79M | -22.6% | -23.0% |
| March 31, 2025 | $315.41M | +2.2% | +0.2% |
| December 31, 2024 | $314.87M | +3.8% | +0.2% |
| September 30, 2024 | $314.33M | +5.5% | +0.2% |
| June 30, 2024 | $313.82M | +7.0% | +1.7% |
| March 31, 2024 | $308.48M | +32.7% | +1.7% |
| December 31, 2023 | $303.23M | +30.9% | +1.8% |
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: